Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMG 329 (Primary) ; AMG 329 (Primary)
Indications Axial spondyloarthritis; Psoriatic arthritis; Rheumatic disorders; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
Focus Adverse reactions; First in man
Sponsors Horizon Therapeutics plc; Viela Bio

01 Aug 2023 Status changed from active, no longer recruiting to completed.
09 Mar 2023 Planned End Date changed from 15 May 2023 to 15 Nov 2023.
09 Mar 2023 Planned primary completion date changed from 15 May 2023 to 15 Nov 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com